UCB to acquire Candid Therapeutics for up to $2.2 billion May 3, 2026 01:10PM
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers May 3, 2026 01:10PM
UCB to acquire Zogenix Jan 19, 2022 01:00AM
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy Jun 5, 2020 07:00AM
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases Oct 10, 2019 07:00AM


Oct 10, 2019 01:22AM UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
Apr 20, 2018 07:00AM UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen